Krystal Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Krystal Biotech

06/05/2025 14:33

Krystal Biotech Inc KRYS.OQ reported quarterly adjusted earnings of $1.20​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 3 cents.  The mean expectation of nine analysts for the quarter was for earnings of $1.37 per share. Wall Street expected results to range from $1.07  to $1.72 per share.

Revenue rose 94.9% to $88.18 million from a year ago; analysts expected $96.24 million.

Krystal Biotech Inc's reported EPS for the quarter was $1.20​.

The company reported quarterly net income of $35.73 million.

Krystal Biotech Inc shares had fallen by 10.0% this quarter and gained 3.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 33.1% in the last three months.​

In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Krystal Biotech Inc is $215.00

This summary was machine generated from LSEG data May 6 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
1.37
1.20
Missed
Dec. 31 2024
1.17
1.52
Beat
Sep. 30 2024
0.90
0.91
Beat
Jun. 30 2024
0.58
0.53
Missed